Inhibrx reports Q2 net loss of $28.7M; cash $186.6M; key trial data expected Q4 2025

Inhibrx Biosciences, Inc.

2025-Q2 EPS reported -$4.65 vs consensus -$2.82 ▼ miss (-65.1%)

Net loss of $28.7M ($1.85/share) vs net income of $1.9B in Q2 2024 due to $2B gain from 101 transaction.
Revenue $1.3M (up from $0.1M); R&D $22.3M (-67% YoY); G&A $6.4M (-93% YoY).
Cash and equivalents $186.6M at June 30, down from $216.5M at March 31.
Ozekibart (INBRX-109) Phase 2 chondrosarcoma trial fully enrolled; results expected by late Oct 2025.
Initial Phase 2 data for INBRX-106 in head/neck cancer + pembrolizumab expected in Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.